<code id='5C9E36E2B6'></code><style id='5C9E36E2B6'></style>
    • <acronym id='5C9E36E2B6'></acronym>
      <center id='5C9E36E2B6'><center id='5C9E36E2B6'><tfoot id='5C9E36E2B6'></tfoot></center><abbr id='5C9E36E2B6'><dir id='5C9E36E2B6'><tfoot id='5C9E36E2B6'></tfoot><noframes id='5C9E36E2B6'>

    • <optgroup id='5C9E36E2B6'><strike id='5C9E36E2B6'><sup id='5C9E36E2B6'></sup></strike><code id='5C9E36E2B6'></code></optgroup>
        1. <b id='5C9E36E2B6'><label id='5C9E36E2B6'><select id='5C9E36E2B6'><dt id='5C9E36E2B6'><span id='5C9E36E2B6'></span></dt></select></label></b><u id='5C9E36E2B6'></u>
          <i id='5C9E36E2B6'><strike id='5C9E36E2B6'><tt id='5C9E36E2B6'><pre id='5C9E36E2B6'></pre></tt></strike></i>

          00:00
          00:00 00:00 LIVE
          buffering
          Replay
          LIVE
          00:00 / 00:00
          LIVE
          CC
          Opacity :
          Share:
          Close

          focus

          author:Wikipedia    - browse:25
          Stock exchange
          Drew Angerer/Getty Images

          Viking Therapeutics said Tuesday that its closely watched oral obesity drug had succeeded in an early-stage trial and that it planned to advance the medicine into the next phase of development. 

          The top-line results released Tuesday were only from a Phase 1 study, which primarily focuses on a drug’s safety. But Viking said that in the study, its medicine led to a roughly 3.3% placebo-adjusted average weight loss after four weeks and that it showed no safety issues.

          advertisement

          In preview notes, analysts had said that investors would want to see between 3% and 4% placebo-adjusted weight loss. Shares of San Diego-based Viking were up more than 20% in pre-market trading Tuesday.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          hotspot